Abstract
RNA interference using synthetic siRNAs to inhibit gene expression in a sequence-specific manner offers a novel opportunity for treating pulmonary diseases including asthma, airway inflammation, and respiratory viral infections. Developing siRNAs as therapeutics will however require chemical modifications to avoid degradation by nucleases, and delivery formulations to improve lung exposure. In the studies summarized here, we compared the time course of exposure in lung tissue of unmodified siRNA and greater than 95% stabilized siRNA.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
